Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

Author(s):

Félix Guerrero-Ramos, MD, PhD, FEBU ,Srikala Sridhar, MD

Key Takeaways

Urologists need oncologists to provide systemic therapy insights and manage immune-related adverse events in combination therapy.
Oncologists rely on urologists for expertise in local disease management and patient selection for combination therapy.
Effective communication and shared decision-making are vital for tailoring treatment plans and monitoring patient progress.
Collaboration enhances patient care and improves clinical outcomes in high-risk non–muscle-invasive bladder cancer.

Panelists discuss how urologists and oncologists must collaborate to improve outcomes for high-risk non–muscle-invasive bladder cancer (NMIBC) patients receiving combination therapy with PD-1/PD-L1 inhibitors and BCG, emphasizing the need for clear communication and coordinated care strategies.

EP: 1.Exploring NMIBC: Overview, Symptoms, Risk Factors and Staging

EP: 2.NMIBC Treatment Insights: Standard of Care, BCG Immune Response, and Patient Outcomes

EP: 3.Exploring PD-1/PD-L1 Pathways and Innovative Treatments for NMIBC

EP: 4.Innovations in NMIBC Treatment: The Synergy of BCG and PD-1/PD-L1 Inhibitors

Now Viewing

EP: 5.Collaborative Strategies: Urologists and Oncologists Enhancing Outcomes for High-Risk NMIBC

EP: 6.Navigating PD-1/PD-L1 Agents: Influential Factors in Choosing the Right Therapy

EP: 7.Phase 3 Trials of PD-1/PD-L1 Inhibitors in NMIBC

EP: 8.Examining the Effects of PD-1/PD-L1 Inhibitor Differences on Patient Outcomes: Adherence, BCG Maintenance, and Resource Management

EP: 9.Exploring Emerging Data in NMIBC

EP: 10.Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC

Video content above is prompted by the following:

What do urologists need from oncologists, and vice versa, in improving outcomes for high-risk non–muscle-invasive bladder cancer patients for combination therapy with PD-1/PD-L1 inhibitors plus BCG?